|
| S. no. | Intervention | Recommendations |
| Drugs | National guidelines | Systematic review | WHO |
|
| 1 | Corticosteroids | (i) To use in severe or critical patients
(ii) Not to use in nonsevere or asymptomatic | (i) For the use of corticosteroids in severe and critical patients, hospitalized COVID-19 patients. Strong recommendation, moderate-quality evidence
(ii) Against the use of corticosteroids in nonsevere patients, hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence | Recommended the use of systematic corticosteroid rather than no corticosteroids in severe and critical COVID-19 patients. |
| 2 | Tocilizumab | (i) To use in patients who have worsened despite the initial 24–48 hours of steroids
(ii) To not use in patients who have not received a trial of steroids or with elevated markers only | For the use of tocilizumab in hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence | Recommended the use of tocilizumab in patients with severe or critical COVID-19 infection. |
| 3 | Ivermectin therapy | This is not recommended in the national guidelines | Against the use of ivermectin therapy in the use of COVID-19 hospitalized patients. Weak recommendation, low-quality evidence | Recommended against the use of ivermectin in patients with COVID-19 |
| 4 | Hydroxychloroquine/chloroquine | There is no role for prophylactic chloroquine and hydroxychloroquine to prevent COVID-19 infection after exposure | Against the use of hydroxychloroquine alone or in combination with other antibiotics in hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence | Recommended against the use of hydroxychloroquine or chloroquine for treatment of COVID-19 |
| 5 | Antibiotics | (i) To use in proven or strong suspicion of secondary infection
(ii) To not use for “prevention” of secondary infections or in patients with no clear evidence of bacterial infection | No evidence available | No evidence available |
| 6 | Anticoagulation therapy | Prophylactic anticoagulation
(i) To use in all hospitalized patients
(ii) To not use in nonsevere or asymptomatic patients
Therapeutic anticoagulation
(i) To use in proven or high suspicion of VTE
(ii) To not use in patients with isolated elevated D-dimers or no evidence of VTE | (i) For the use of anticoagulant therapeutic doses. Therapeutic: strong recommendation, moderate-quality evidence
(ii) For the use of prophylactic dose anticoagulants to treat COVID-19 hospitalized patients. Prophylactic: strong recommendation, moderate-quality evidence | No evidence available |
| 7 | Remdesivir | (i) To use in severe patients with less than 10 days of symptoms
(ii) To not use in nonsevere, asymptomatic, or critical patients or in whom symptoms are longer than 10 days | For the use of remdesivir in hospitalized COVID-19 patients. Recommendation, high-quality evidence | Conditional recommendation against administering remdesivir in addition to usual care. |
| 8 | Lopinavir/ritonavir | (i) To use in severe patients with less than 10 days of symptoms
(ii) To not use in nonsevere, asymptomatic, or critical patients or in whom symptoms are longer than 10 days | Against the use of ritonavir/lopinavir in hospitalized COVID-19 patients. No recommendation, moderate-quality evidence | Recommended against administering lopinavir/ritonavir for treatment of COVID-19. |
| 9 | Convalescent plasma | No evidence available | Against the use of convalescent plasma in the management of hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence | No evidence available |
| 10 | Famotidine | Not recommended in the national guidelines | For the use of famotidine in hospitalized COVID-19 patients. Weak recommendation, low-quality evidence | No evidence available |
| 11 | Immunoglobulin therapy | No evidence available | For the use of immunoglobulin therapy in hospitalized COVID-19 patients. Weak recommendation, moderate-quality evidence | No evidence available |
| 12 | Colchicine | No evidence available | Against the use of colchicine in hospitalized COVID-19 patients. No recommendation, low-quality evidence | No evidence available |
|
